Opthalmologic Outcomes- Tamoxifen trials

Trial NameNLength of Treatment (years)Length of FU (years)PlaceboTamoxifenRR95% CINotes
PlaceboTamoxifenNo.RateNo.Rate
Royal Marsden
Powell, 200726
Cataracts
12331238813.230.18120.703.991.13–14.14Active Treatment
Italian
Veronesi, 200729
“Opthamologic diseases”
2708270051111811.6511211.390.980.75– 1.27Active Treatment
IBIS
Cuzick, 200720: Cataracts3575357960 months96 months341.90291.630.850.52–1.40Active
Cataracts : Post20381.921.12–3.29Active
Eye complaints : Active89690110.93–1.09Self report
Eye complaints: Post5976221.050.95–1.17
NASABP
Fisher, 200523: Cataracts613161015722.927.81.211.10–1.34
Cataracts surgery7.5810.541.391.19–1.63
Fisher, 199824: Cataracts61316101569 months50721.7257424.821.141.01–1.29
Cataracts surgery7331144.721.571.16–2.14

From: Appendix D, Evidence Tables

Cover of Comparative Effectiveness of Medications To Reduce Risk of Primary Breast Cancer in Women
Comparative Effectiveness of Medications To Reduce Risk of Primary Breast Cancer in Women [Internet].
AHRQ Comparative Effectiveness Reviews, No. 17.
Nelson HD, Fu R, Humphrey L, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.